Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease

JAMA

Volumn 294, Issue 1, 2005, Pages 81-90

  Morris, Claudia R ^a   Kato, Gregory J ^b,c   Poljakovic, Mirjana ^e   Wang, Xunde ^b,c   Blackwelder, William C ^c   Sachdev, Vandana ^d   Hazen, Stanley L ^f   Vichinsky, Elliott P ^a   Morris, Sidney M ^e   Gladwin, Mark T ^b,c  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CITRULLINE; HEMOGLOBIN; NITRIC OXIDE; ORNITHINE; AMINO ACID;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID DEFICIENCY; AMINO ACID METABOLISM; ARTICLE; BIOAVAILABILITY; COMMUNITY HOSPITAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIUM LESION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME RELEASE; ERYTHROCYTE; FEMALE; FOLLOW UP; HEALTH HAZARD; HEALTH STATUS; HUMAN; INFLAMMATION; INTRAVASCULAR HEMOLYSIS; MALE; MOLECULAR MECHANICS; MORTALITY; OUTPATIENT; OUTPATIENT DEPARTMENT; PATHOGENESIS; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; SOLUBILITY; SURVIVAL; UNITED STATES; UNIVERSITY HOSPITAL; URBAN AREA; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AMINO ACIDS; ANEMIA, SICKLE CELL; ARGINASE; ARGININE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; ORNITHINE; PROPORTIONAL HAZARDS MODELS;

EID: 21444441271     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.1.81     Document Type: Article

References (75)

1. Morris CR, Kuypers FA, Larkin S, Vichinsky E, Styles L. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol. 2000;22:515-520.
2. Enwonwu CO. Increased metabolic demand for arginine in sickle cell anaemia. Med Sci Res. 1989;17:997-998.
3. VanderJagt DJ, Kanellis GJ, Isichei C, Pastuszyn A, Glew RH. Serum and urinary amino acid levels in sickle cell disease. J Trop Pediatr. 1997;43:220-225.
4. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to increase nitric oxide production in sickle cell disease. Br J Haematol. 2000;111:498-500.
5. Reiter C, Wang X, Tanus-Santos J, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sicklecell disease. Nat Med. 2002;8:1383-1389.
6. Aslan M, Ryan T, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001;98:15215-15220.
7. Dias-Da-Motta P, Arruda V, Muscara M, Saad S. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. Br J Haematol. 1996;93:333-340.
8. Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003;10:99-107.
9. Gladwin M, Schechter A, Ognibene F, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107:271-278.
10. Kaul DK, Liu XD, Fabry ME, Nagel RL. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol. 2000;278:H1799-H1806.
11. Diwan BA, Gladwin MT, Moguchi CT, Ward JM, Fitzhugh AL, Buzard GS. Renal pathology in hemizygous sickle cell mice. Toxicol Pathol. 2002;30:254-262.
12. Bank N, Aynedjian H, Qiu J, et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int. 1996;50:184-189.
13. Kaul DK, Liu X, Chang H, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114:1136-1145.
14. Xia Y, Dawson V, Dawson T, Snyder S, Zweier J. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitritemediated cellular injury. Proc Natl Acad Sci U S A. 1996; 93:6770-6774.
15. 2+/calmodulin- dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992;281:627-630.
16. Waugh W, Daeschner C, Files B, Gordon D. Evidence that L-arginine is a key amino acid in sickle cell anemia: a preliminary report. Nutr Res. 1999;19:501-518.
17. Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol. 2003;25:629-634.
18. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63-69.
19. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun. 2000;275:715-719.
20. Morris SM Jr. Regulation of arginine availability and its impact on NO synthesis. In: Ignarro L, ed. Nitric Oxide: Biology and Pathobiology. San Diego, Calif: Academic Press; 2000:187-197.
21. Boucher JL, Moali C, Tenu JP. Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol Life Sci. 1999;55:1015-1028.
22. Kim P, Iyer R, Lu K, et al. Expression of the liver form of arginase in erythrocytes. Mol Genet Metab. 2002;76:100-110.
23. Azizi E, Dror Y, Wallis K. Arginase activity in erythrocytes of healthy and ill children. Clin Chim Acta. 1970;28:391-396.
24. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22:87-105.
25. Mori M, Gotoh T. Relationship between arginase activity and nitric oxide production. In: Ignarro L, ed. Nitric Oxide: Biology and Pathobiology. San Diego, Calif: Academic Press; 2000:199-208.
26. Closs EI, Mann GE. Membrane transport of Larginine and cationic amino acid analogs. In: Ignarro L, ed. Nitric Oxide: Biology and Pathobiology. San Diego, Calif: Academic Press; 2000:225-241.
27. Closs EI. Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens. 2002;11:99-107.
28. Morris CR, Gardner J, Hagar W, Vichinsky EP. Pulmonary hypertension in sickle cell disease: a common complication for both adults and children. Blood. 2004;104:463a.
29. Gladwin M, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886-895.
30. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis LF. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74:626-628.
31. Castro O, Hoque M, Brown M. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101:1257-1261.
32. Aessopos A, Stamatelow G, Skoumas V, Vassilopoulos G, Mantzourani M, Loulopoulos D. Pulmonary hypertension and right heart failure in patients with Bthalassemia intermedia. Chest. 1995;107:50-53.
33. Verresen D, De Backer W, Van Meerbeeck J, Neetens I, Van Marck E, Vermeire P. Spherocytosis and pulmonary hypertension: coincidental occurrence or causal relationship? Eur Respir J. 1991;4:629-631.
34. Heller PG, Grinberg AR, Lencioni M, Molina MM, Roncoroni AJ. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 1992;102:642-643.
35. Labrune P, Sittoun J, Duvaltier I, et al. Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency. Eur J Pediatr. 1999;158:734-739.
36. Stuard ID, Heusinkveld RS, Moss AJ. Microangiopathic haemolytic anemia and thrombocytopenia in primary pulmonary hypertension. N Engl J Med. 1972;287:869-870.
37. Jubelirer SJ. Primary pulmonary hypertension: its association with microangiopathic haemolytic anemia and thrombocytopenia. Arch Intern Med. 1991;151:1221-1223.
38. Chou R, DeLoughery TG. Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency. Am J Hematol. 2001;67:197-199.
39. Jison ML, Gladwin MT. Hemolytic anemiaassociated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. Am J Respir Crit Care Med. 2003;168:3-4.
40. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.
41. Mehta S, Stewart D, Langleben D, Levy R. Shortterm pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 1995;92:1539-1545.
42. Archer S, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1061-1067.
43. Cooper C, Landzberg M, Anderson T, et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation. 1996;93:266-271.
44. Kaneko F, Arroliga A, Dweik R, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:917-923.
45. Xu W, Kaneko TF, Zheng S, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004;18:1746-1748.
46. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1-17.
47. Featherston WR, Rogers QR, Freedland RA. Relative importance of kidney and liver in synthesis of arginine by the rat. Am J Physiol. 1973;224:127-129.
48. Morris SM Jr, Kepka-Lenhart D, Chen L. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol. 1998;275:E740-E747.
49. Wang X, Tanus-Santos JE, Reiter CD, et al. Biological activity of nitric oxide in the plasmatic compartment. Proc Natl Acad Sci U S A. 2004;101:11477-11482.
50. Hosmer D, Lemeshow S. Applied Survival Analysis. New York, NY: John Wiley & Sons; 1999.
51. Hebbel RP, Osarogiagbon KD. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129-151.
52. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104:270-280.
53. Belfiore F. Enzymatic activities of the blood serum in thalassemia and in thalassodrepanocytosis. Riforma Med. 1964;78:1052-1055.
54. Reynolds J, Follette JH, Valentine WH. The arginase activity of erythrocytes and leukocytes with particular reference to pernicious anemia and thalassemia major. J Lab Clin Med. 1957;50:78-92.
55. Raghupathy R, Haider MZ, Azizieh F, Abdelsalam R, D'Souza TM, Adekile AD. Th1 and Th2 cytokine profiles in sickle cell disease. Acta Haematol. 2000;103:197-202.
56. Meurs H, McKay S, Maarsingh H, et al. Increased arginase activity underlies allergen-induced deficiency of cNOS-dervied nitric oxide and airway hyperresponsiveness. Br J Pharmacol. 2002;136:391-398.
57. Meurs H, Maarsingh H, Zaagsma J. Arginase and asthma: novel insights into nitric oxide homeostatis and airway hyperresponsiveness. Trends Pharmacol Sci. 2003;24:450-455.
58. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, Morris SM Jr. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med. 2004;170:148-153.
59. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111:1863-1874.
60. Komai M, Tanaka H, Masuda T, et al. Role of Th2 responses in the development of allergen-induced airway remodeling in a murine model of allergic asthma. Br J Pharmacol. 2003;138:912-920.
61. Chung KF, Barnes PJ. Cytokines in asthma. Thorax. 1999;54:825-857.
62. Leong MA, Dampier C, Varlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr. 1997;131:278-283.
63. Koumbourlis A, Zar H, Hurlet-Jensen A, Goldberg M. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr. 2001;138:188-192.
64. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337:1584-1590.
65. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 1998;101:1899-1904.
66. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98:1955-1962.
67. Embury SH, Matsuei NM, Ramanujam S, et al. The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Blood. 2004;104:3378-3385.
68. Wood K, Russell J, Hebbel RP, Grange DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation. 2004;11:377-385.
69. Mansoor MA, Seljeflot I, Arnesen H, et al. Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia. Clin Biochem. 2004;37:408-414.
70. Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappie S, Catapano AL. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab. 2004;89:2946-2950.
71. Marchesi S, Lupattelli G, Lombardini R, et al. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther. 2003;28:419-424.
72. Shores J, Peterson J, VanderJagt D, Glew RH. Reduced cholesterol levels in African-American adults with sickle cell disease. J Natl Med Assoc. 2003;95:813-817.
73. Grunfeld C, Feingold KR. Regulation of lipid metabolism by cytokines during host defense. Nutrition. 1996;12:S24-S26.
74. Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology. 2003;8:329-337.
75. Schnog JJ, Jager EH, van der Dijs FP, et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371-375.